Table 4.
HIN-1/RASSF1A panel | RIL/CDH13 panel | |||||
Number negative (percentage) | Number positive (percentage) | p value | Number negative (percentage) | Number positive (percentage) | p value | |
Tumor size | 0.502 | 0.999 | ||||
1 | 11 (20) | 8 (24) | 14 (22) | 5 (19) | ||
2 | 20 (36) | 16 (47) | 25 (39) | 11 (42) | ||
3 | 12 (21) | 6 (18) | 13 (20) | 5 (19) | ||
4 | 13 (23) | 4 (12) | 12 (19) | 5 (19) | ||
Tumor grade (BNG) | 0.015 | 0.162 | ||||
1 + 2 | 25 (45) | 25 (74) | 39 (61) | 11 (44) | ||
3 | 30 (55) | 9 (26) | 25 (39) | 14 (56) | ||
Tumor stage | 0.16 | 0.745 | ||||
1 | 8 (14) | 7 (21) | 12 (19) | 3 (12) | ||
2 | 20 (36) | 17 (50) | 25 (39) | 12 (46) | ||
3 | 28 (50) | 10 (29) | 27 (42) | 11 (42) | ||
Lymph-node metastasis | 0.558 | 0.78 | ||||
PN0 | 24 (43) | 15 (44) | 26 (41) | 13 (50) | ||
PN1 | 16 (29) | 12 (35) | 22 (34) | 6 (23) | ||
PN2 | 5 (9) | 4 (12) | 6 (9) | 3 (12) | ||
PN3 | 11 (20) | 3 (9) | 10 (16) | 4 (15) | ||
Lymphatic invasion | 0.244 | 0.805 | ||||
1 | 25 (52) | 20 (67) | 32 (59) | 13 (54) | ||
2 | 23 (48) | 10 (33) | 22 (41) | 11 (46) | ||
Vascular invasion | 0.346 | 0.623 | ||||
1 | 26 (54) | 20 (67) | 33 (61) | 13 (54) | ||
2 | 22 (46) | 10 (33) | 21 (39) | 11 (46) | ||
ER status | < 0.001 | 0.001 | ||||
Positive | 22 (42) | 30 (88) | 44 (72) | 8 (31) | ||
Negative | 31 (58) | 4 (12) | 17 (28) | 18 (69) | ||
PR status | < 0.001 | 0.033 | ||||
Positive | 16 (30) | 24 (71) | 33 (54) | 7 (27) | ||
Negative | 37 (70) | 10 (29) | 28 (46) | 19 (73) | ||
HR status | < 0.001 | 0.001 | ||||
Positive | 24 (45) | 31 (91) | 46 (75) | 9 (35) | ||
Negative | 29 (55) | 3 (9) | 15 (25) | 17 (65) | ||
HER-2/neu status | 0.041 | 0.999 | ||||
Positive | 7 (14) | 0 (0) | 5 (9) | 2 (8) | ||
Negative | 43 (86) | 30 (100) | 50 (91) | 23 (92) | ||
Triple-negative | 0.001 | < 0.001 | ||||
No | 33 (59) | 31 (91) | 53 (83) | 11 (42) | ||
Yes | 23 (41) | 3 (9) | 11 (17) | 15 (58) |
BNG, Black's nuclear grade; ER, estrogen receptor; HR, hormone receptor; PR, progesterone receptor.